NYSEAMERICAN : ATNM
Actinium Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.4918 USD (Oct 30, 2026, 1:05 PM EDT) · Market cap 46.90M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 46.53M |
| Enterprise Value | 11.40M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 31.44M |
| Shares Outstanding | 31.44M |
| Shares Change (YoY) | +0.28% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | 0.59% |
| Owned by Institutions (%) | 16.18% |
| Float | 31.26M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 4.16 |
| Forward PE | n/a |
| PS Ratio | 1.33 |
| Forward PS | n/a |
| PB Ratio | 1.54 |
| P/TBV Ratio | 1.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 1.01 |
| EV / Sales | 0.32 |
| EV / EBITDA | 1.16 |
| EV / EBIT | 1.19 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.08 |
| Quick Ratio | 3.94 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.13 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 45.86% |
| Return on Assets (ROA) | 11.58% |
| Return on Invested Capital (ROIC) | 23.00% |
| Return on Capital Employed (ROCE) | 30.93% |
| Weighted Average Cost of Capital (WACC) | 5.53% |
| Revenue Per Employee | $1.30M |
| Profits Per Employee | $418,815 |
| Employee Count | 27 |
| Asset Turnover | 0.68 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.26 |
| 52-Week Price Change | +1.37% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.12 |
| Relative Strength Index (RSI) | 60.97 |
| Average Volume (20 Days) | 257,628 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 631,234 |
| Short Previous Month | 707,672 |
| Short % of Shares Out | 2.01% |
| Short % of Float | 2.02% |
| Short Ratio (days to cover) | 5.94 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 35.09M |
| Gross Profit | 35.09M |
| Operating Income | 9.56M |
| Pretax Income | 11.31M |
| Net Income | 11.31M |
| EBITDA | 9.79M |
| EBIT | 9.56M |
| Earnings Per Share (EPS) | $0.36 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 36.47M |
| Total Debt | 1.34M |
| Net Cash | 35.13M |
| Net Cash Per Share | $1.12 |
| Equity (Book Value) | 30.30M |
| Book Value Per Share | 0.96 |
| Working Capital | 28.48M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -22.66M |
| Capital Expenditures | -584,000 |
| Depreciation & Amortization | 235,000 |
| Net Borrowing | -10,000 |
| Free Cash Flow | -23.25M |
| FCF Per Share | -$0.74 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | 27.23% |
| Pretax Margin | 32.23% |
| Profit Margin | 32.23% |
| EBITDA Margin | 27.90% |
| EBIT Margin | 27.23% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.28% |
| Shareholder Yield | n/a |
| Earnings Yield | 24.05% |
| FCF Yield | -49.96% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.00 |
| Price Target Difference | 170.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 478.90% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 11, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -8.41 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |